Jefferies Starts Aegerion Pharmaceuticals (AEGR) at Buy

Jefferies initiates coverage on Aegerion Pharmaceuticals (NASDAQ: AEGR) with a Buy. PT $20.00.

The firm comments, "Aegerion has one product, lomitapide, for treatment of phenotypic HoFH. Based on positive Ph3 data, the company plans to file for approval in 1Q12 in the U.S./Europe. While regulatory risks remain (AdComm panel, FDA action), given our 75% probability-adjusted valuation, we think AEGR offers an attractive opportunity for medium/high-risk tolerant investors at current levels. We initiate coverage with a Buy rating and $20 price target."

For more ratings news on Aegerion Pharmaceuticals click here and for the rating history of Aegerion Pharmaceuticals click here.

Shares of Aegerion Pharmaceuticals closed at $13.14 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Assumes Honeywell International (HON) at Hold
• Jefferies Starts Aehr Test Systems (AEHR) at Buy
• ThinkEquity Starts Deep Isolation Nuclear (DBHL) at Buy